Synaptotagmin-like protein 2 (SYTL2)

Synaptotagmin-like protein 2 (SYTL2) is a member of the C2 domain-containing synaptotagmin-like protein family that functions as a Rab effector, primarily interacting with GTP-bound Rab27A. SYTL2 regulates vesicle trafficking and exocytosis processes, including cytotoxic granule release in lymphocytes and specialized granule recruitment in pancreatic alpha cells. Its function is mediated through several domains, including an SHD (Rab-binding region) and tandem C2 domains responsible for phospholipid interactions. SYTL2 has diverse biological roles in controlling cell periphery melanosome positioning, tubulogenesis, and vesicle transport. Epigenetically regulated SYTL2 expression promotes metastatic behavior in ovarian cancer cells, and correlates with adverse prognosis. Multiple transcript variants and isoforms exist due to alternative splicing. SYTL2 is implicated in cancer (ovarian, bladder), inflammatory and neurodegenerative diseases, and rare disorders such as Griscelli Syndrome.

Other names

SLP2KIAA1597SGA72MSLP2AFLJ20163FLJ21219exophilin-4CHR11SYTMGC102768PPP1R151Breast cancer-associated antigen SGA-72MEXO4

No drugs directly targeting SYTL2 are identified. Epigenetic modification agents such as 5-aza-dC increase SYTL2 expression by demethylating its promoter.